143 related articles for article (PubMed ID: 37247082)
41. Clinical outcomes after incomplete cycles of R-CHOP for diffuse large B-cell lymphoma: 10 years' real-world experience in a single institute.
Yoon J; Kim KH; Kim JS; Byun JM; Hong J; Shin DY; Koh Y; Kim TM; Kim I; Yoon SS; Heo DS; Park H; Park JH
Ann Hematol; 2023 Jun; 102(6):1467-1476. PubMed ID: 37099081
[TBL] [Abstract][Full Text] [Related]
42. MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma.
Due H; Schönherz AA; Ryø L; Primo MN; Jespersen DS; Thomsen EA; Roug AS; Xiao M; Tan X; Pang Y; Young KH; Bøgsted M; Mikkelsen JG; Dybkær K
Blood Adv; 2019 Apr; 3(7):1185-1196. PubMed ID: 30967394
[TBL] [Abstract][Full Text] [Related]
43. Prevalence and clinicopathologic features of CD30-positive de novo diffuse large B-cell lymphoma in Chinese patients: a retrospective study of 232 cases.
Gong QX; Lu TX; Liu C; Wang Z; Liang JH; Xu W; Li JY; Zhang ZH; Chen Q
Int J Clin Exp Pathol; 2015; 8(12):15825-35. PubMed ID: 26884853
[TBL] [Abstract][Full Text] [Related]
44. Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan.
Tanaka T; Shimada K; Yamamoto K; Hirooka Y; Niwa Y; Sugiura I; Kitamura K; Kosugi H; Kinoshita T; Goto H; Nakamura S
Ann Hematol; 2012 Mar; 91(3):383-90. PubMed ID: 21822617
[TBL] [Abstract][Full Text] [Related]
45. 5-Hydroxymethylcytosine profiles of cfDNA are highly predictive of R-CHOP treatment response in diffuse large B cell lymphoma patients.
Chen HY; Zhang WL; Zhang L; Yang P; Li F; Yang ZR; Wang J; Pang M; Hong Y; Yan C; Li W; Liu J; Xu N; Chen L; Xiao XB; Qin Y; He XH; Liu H; Zhu HC; He C; Lin J; Jing HM
Clin Epigenetics; 2021 Feb; 13(1):33. PubMed ID: 33573703
[TBL] [Abstract][Full Text] [Related]
46. Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era.
de Oliveira Costa R; Hallack Neto A; Siqueira S; Lage LA; de Paula HM; Coutinho AM; Pereira J
Nucl Med Commun; 2016 Oct; 37(10):1095-101. PubMed ID: 27281359
[TBL] [Abstract][Full Text] [Related]
47. Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma.
Sparano JA; Lee JY; Kaplan LD; Ramos JC; Ambinder RF; Wachsman W; Aboulafia D; Noy A; Henry DH; Ratner L; Cesarman E; Chadburn A; Mitsuyasu R
Haematologica; 2021 Mar; 106(3):730-735. PubMed ID: 32107337
[TBL] [Abstract][Full Text] [Related]
48. Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma.
Zhang MC; Fang Y; Wang L; Cheng S; Fu D; He Y; Zhao Y; Wang CF; Jiang XF; Song Q; Xu PP; Zhao WL
Clin Epigenetics; 2020 Oct; 12(1):160. PubMed ID: 33097085
[TBL] [Abstract][Full Text] [Related]
49. The role of maintenance therapy in patients with diffuse large B cell lymphoma: A systematic review and meta-analysis.
Rozental A; Gafter-Gvili A; Vidal L; Raanani P; Gurion R
Hematol Oncol; 2019 Feb; 37(1):27-34. PubMed ID: 30216478
[TBL] [Abstract][Full Text] [Related]
50. Chemotherapy for management of localised high-grade gastric B-cell lymphoma: how much is necessary?
Raderer M; Chott A; Drach J; Montalban C; Dragosics B; Jäger U; Püspök A; Osterreicher C; Zielinski CC
Ann Oncol; 2002 Jul; 13(7):1094-8. PubMed ID: 12176789
[TBL] [Abstract][Full Text] [Related]
51. FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study.
Mikhaeel NG; Cunningham D; Counsell N; McMillan A; Radford JA; Ardeshna KM; Lawrie A; Smith P; Clifton-Hadley L; O'Doherty MJ; Barrington SF
Br J Haematol; 2021 Feb; 192(3):504-513. PubMed ID: 32621535
[TBL] [Abstract][Full Text] [Related]
52. Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S.
Yang X; Laliberté F; Germain G; Raut M; Duh MS; Sen SS; Lejeune D; Desai K; Armand P
Oncologist; 2021 May; 26(5):e817-e826. PubMed ID: 33616256
[TBL] [Abstract][Full Text] [Related]
53. Safety and efficacy of durvalumab with R-CHOP or R
Nowakowski GS; Willenbacher W; Greil R; Larsen TS; Patel K; Jäger U; Manges RF; Trümper L; Everaus H; Kalakonda N; Brown P; Jørgensen JM; Cunningham D; Dell'Aringa J; Fox B; Rubio ND; Kilavuz N; Casadebaig ML; Manzke O; Munoz J
Int J Hematol; 2022 Feb; 115(2):222-232. PubMed ID: 34797531
[TBL] [Abstract][Full Text] [Related]
54. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
55. Impact of inadequate doses of rituximab in the treatment of diffuse large B cell lymphoma in Malaysian patients.
Gan GG; Subramaniam R; Bee PC; Chin EF; Abdul-Halim H; Tai MC
Asian Pac J Cancer Prev; 2014; 15(4):1703-6. PubMed ID: 24641394
[TBL] [Abstract][Full Text] [Related]
56. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.
Shi Z; Das S; Okwan-Duodu D; Esiashvili N; Flowers C; Chen Z; Wang X; Jiang K; Nastoupil LJ; Khan MK
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):569-77. PubMed ID: 23540349
[TBL] [Abstract][Full Text] [Related]
57. Extranodal site of diffuse large B-cell lymphoma and the risk of R-CHOP chemotherapy resistance and early relapse.
Ting CY; Gan GG; Bee-Lan Ong D; Tan SY; Bee PC
Int J Clin Pract; 2020 Oct; 74(10):e13594. PubMed ID: 32583545
[TBL] [Abstract][Full Text] [Related]
58. Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial.
McMillan AK; Phillips EH; Kirkwood AA; Barrans S; Burton C; Rule S; Patmore R; Pettengell R; Ardeshna KM; Lawrie A; Montoto S; Paneesha S; Clifton-Hadley L; Linch DC
Ann Oncol; 2020 Sep; 31(9):1251-1259. PubMed ID: 32464282
[TBL] [Abstract][Full Text] [Related]
59. Factors affecting survival in elderly patients with diffuse large B-Cell lymphoma.
Ulu BU; Yiğenoğlu TN; Başcı S; Bakırtaş M; Şahin D; Darçın T; Yaman S; Bozan E; Seçilmiş S; Candır BA; Yıldız J; İskender D; Baysal NA; Çakar MK; Dal MS; Altuntaş F
Leuk Res; 2021 Nov; 110():106700. PubMed ID: 34481125
[TBL] [Abstract][Full Text] [Related]
60. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
